Utilities for COPD GOLD Stages: Cost-Effectiveness Model for Respiratory Infection Testing

A 40-year model-based cost-utility analysis evaluating the Biofire Film Array Respiratory Panel RP 2.1+ test for COPD patients. The dataset, created by Raymond Oppong and last updated in April 2026, contains results indicating the test is cost-saving and more effective, with potential annual savings estimated between £118 million and £18.6 billion.

Use Cases

• Modeling the cost-effectiveness of diagnostic tests for COPD exacerbations based on the described 40-year healthcare perspective.
• Estimating potential savings from reductions in antimicrobial resistance based on the two AMR accounting approaches described.
• Comparing intervention arms in economic evaluations based on the reported cost and QALY differences.
• Informing healthcare resource allocation decisions for respiratory infection management based on the study's conclusions.

Strengths

• Model parameters informed by a targeted literature review and expert opinions.
• Includes two distinct approaches to account for antimicrobial resistance costs.
• File size is 5.5 KB, indicating a focused and likely well-structured model.

Limitations

• Row count and column-level documentation are unknown; field semantics must be inferred after download.
• The dataset's small scale (5.5 KB) suggests it contains summary model outputs, not raw patient-level data.

Provenance

Source

Raymond Oppong via figshare

Collection Method

Model-based analysis informed by literature review and expert opinion.

Time Range

Model horizon of 40 years.

Freshness

Last updated 2026-04-27 17:26:48; freshness should be verified.

Geography

null